ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer's and a lot more
ARCH Venture is doubling — and tripling and quadrupling — down on the belief that the 2020s will be neuroscience’s decade.
The VC firm, known for periodically launching massive companies from scratch, announced on Thursday the creation of Neumora, a biotech ARCH’s partners believe can finally crack a set of well-known neurodegenerative and psychiatric diseases that have long eluded drugmakers. The company, whose existence was first reported by Endpoints News in August, emerges from stealth with $500 million in the bank — $400 million from ARCH and other VCs and $100 million equity investment as part of a collaboration with Amgen.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.